Quick Answer
PTC THERAPEUTICS, INC. reported Net Income Loss of $682.64 million for the year ending 2025.
- PTC THERAPEUTICS, INC. showed an increase of +287.9% in Net Income Loss from 2024 to 2025.
- This data is from PTC THERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on February 19, 2026.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2013: -$17.89 million | Q1 2014: -$14.10 million | Q2 2014: -$25.10 million | Q3 2014: -$27.28 million | Q4 2014: -$27.27 million | Q1 2015: -$37.92 million | Q2 2015: -$38.36 million | Q3 2015: -$43.22 million | Q4 2015: -$50.95 million | Q1 2016: -$41.23 million | Q2 2016: -$38.91 million | Q3 2016: -$35.17 million | Q4 2016: -$26.80 million | Q1 2017: -$29.06 million | Q2 2017: -$17.48 million | Q3 2017: -$33.74 million | Q4 2017: $1.27 million | Q1 2018: -$19.26 million | Q2 2018: -$9.52 million | Q3 2018: -$50.97 million | Q4 2018: -$48.33 million | Q1 2019: -$72.11 million | Q2 2019: -$41.79 million | Q3 2019: -$60.00 million | Q4 2019: -$77.68 million | Q1 2020: -$112.69 million | Q2 2020: -$181.43 million | Q3 2020: -$69.69 million | Q4 2020: -$74.35 million | Q1 2021: -$128.64 million | Q2 2021: -$118.37 million | Q3 2021: -$133.62 million | Q1 2022: -$126.73 million | Q2 2022: -$152.09 million | Q3 2022: -$109.32 million | Q1 2023: -$138.96 million | Q2 2023: -$198.88 million | Q3 2023: -$132.97 million | Q1 2024: -$91.58 million | Q2 2024: -$99.18 million | Q3 2024: -$106.65 million | Q1 2025: $866.56 million | Q2 2025: -$64.85 million | Q3 2025: $15.90 million.
- Over the full 15 years of available data (2011 to 2025), PTC THERAPEUTICS, INC.'s Net Income Loss has grown by 2,108.9%.
- Historical annual values: Fiscal year 2025: $682.64 million | Fiscal year 2024: -$363.30 million | Fiscal year 2023: -$626.60 million | Fiscal year 2022: -$559.02 million | Fiscal year 2021: -$523.90 million | Fiscal year 2020: -$438.16 million | Fiscal year 2019: -$251.58 million | Fiscal year 2018: -$128.08 million | Fiscal year 2017: -$79.00 million | Fiscal year 2016: -$142.11 million | Fiscal year 2015: -$170.45 million | Fiscal year 2014: -$93.75 million | Fiscal year 2013: -$51.57 million | Fiscal year 2012: -$26.24 million | Fiscal year 2011: $30.90 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: